InspireMD, Inc. Logo

InspireMD, Inc.

NSPR

(1.0)
Stock Price

2,60 USD

-38.45% ROA

-55.36% ROE

-5.05x PER

Market Cap.

61.590.912,00 USD

3.6% DER

0% Yield

-318.95% NPM

InspireMD, Inc. Stock Analysis

InspireMD, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

InspireMD, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (3%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.31x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROE

Negative ROE (-74.37%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-34.49%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

InspireMD, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

InspireMD, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

InspireMD, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

InspireMD, Inc. Revenue
Year Revenue Growth
2009 0
2010 0 0%
2011 6.004.000 100%
2012 5.349.000 -12.25%
2013 4.873.000 -9.77%
2014 2.818.000 -72.92%
2015 2.310.000 -21.99%
2016 1.894.000 -21.96%
2017 2.761.000 31.4%
2018 3.601.000 23.33%
2019 3.721.000 3.22%
2020 2.485.000 -49.74%
2021 4.495.000 44.72%
2022 5.171.000 13.07%
2023 6.224.000 16.92%
2023 6.205.000 -0.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

InspireMD, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 2.474.000 100%
2012 3.988.000 37.96%
2013 4.156.000 4.04%
2014 8.744.000 52.47%
2015 3.642.000 -140.09%
2016 1.291.000 -182.11%
2017 1.276.000 -1.18%
2018 1.535.000 16.87%
2019 2.954.000 48.04%
2020 2.233.000 -32.29%
2021 5.158.000 56.71%
2022 7.810.000 33.96%
2023 8.440.000 7.46%
2023 7.981.000 -5.75%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

InspireMD, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 3.825
2010 15.476 75.28%
2011 12.275.000 99.87%
2012 13.883.000 11.58%
2013 8.973.000 -54.72%
2014 9.125.000 1.67%
2015 6.387.000 -42.87%
2016 5.000.000 -27.74%
2017 5.184.000 3.55%
2018 4.830.000 -7.33%
2019 5.222.000 7.51%
2020 6.127.000 14.77%
2021 7.405.000 17.26%
2022 8.356.000 11.38%
2023 12.364.000 32.42%
2023 11.104.000 -11.35%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

InspireMD, Inc. EBITDA
Year EBITDA Growth
2009 -3.825
2010 -6.976 45.17%
2011 -13.781.000 99.95%
2012 -16.225.000 15.06%
2013 -14.865.000 -9.15%
2014 -23.698.000 37.27%
2015 -12.521.000 -89.27%
2016 -7.648.000 -63.72%
2017 -8.232.000 7.09%
2018 -7.611.000 -8.16%
2019 -9.816.000 22.46%
2020 -10.380.000 5.43%
2021 -14.555.000 28.68%
2022 -18.713.000 22.22%
2023 -22.556.000 17.04%
2023 -20.655.000 -9.2%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

InspireMD, Inc. Gross Profit
Year Gross Profit Growth
2009 0
2010 0 0%
2011 2.993.000 100%
2012 2.500.000 -19.72%
2013 2.590.000 3.47%
2014 784.000 -230.36%
2015 -296.000 364.86%
2016 102.000 390.2%
2017 585.000 82.56%
2018 995.000 41.21%
2019 756.000 -31.61%
2020 83.000 -810.84%
2021 754.000 88.99%
2022 1.117.000 32.5%
2023 1.752.000 36.24%
2023 1.807.000 3.04%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

InspireMD, Inc. Net Profit
Year Net Profit Growth
2009 -3.825
2010 -23.976 84.05%
2011 -14.665.000 99.84%
2012 -17.597.000 16.66%
2013 -29.258.000 39.86%
2014 -25.095.000 -16.59%
2015 -15.585.000 -61.02%
2016 -8.461.000 -84.2%
2017 -8.438.000 -0.27%
2018 -7.240.000 -16.55%
2019 -10.040.000 27.89%
2020 -10.544.000 4.78%
2021 -14.918.000 29.32%
2022 -18.491.000 19.32%
2023 -20.712.000 10.72%
2023 -19.916.000 -4%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

InspireMD, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 -956
2010 -3.425 72.09%
2011 -7.332.500 99.95%
2012 -9.218 -79454.08%
2013 -5.851.600 99.84%
2014 -4.182.500 -39.91%
2015 -1.416.818 -195.2%
2016 -155.793 -809.42%
2017 -4.266 -3552.83%
2018 -235 -1714.89%
2019 -72 -226.39%
2020 -7 -1100%
2021 -2 -200%
2022 -2 0%
2023 -1 0%
2023 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

InspireMD, Inc. Free Cashflow
Year Free Cashflow Growth
2009 -825
2010 -18.981 95.65%
2011 -6.142.000 99.69%
2012 -8.870.000 30.76%
2013 -10.502.000 15.54%
2014 -19.495.000 46.13%
2015 -11.612.000 -67.89%
2016 -7.544.000 -53.92%
2017 -8.389.000 10.07%
2018 -7.673.000 -9.33%
2019 -10.094.000 23.98%
2020 -9.169.000 -10.09%
2021 -13.554.000 32.35%
2022 -16.015.000 15.37%
2023 -4.139.000 -286.93%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

InspireMD, Inc. Operating Cashflow
Year Operating Cashflow Growth
2009 -825
2010 -18.981 95.65%
2011 -6.003.000 99.68%
2012 -8.580.000 30.03%
2013 -10.300.000 16.7%
2014 -19.362.000 46.8%
2015 -11.596.000 -66.97%
2016 -7.495.000 -54.72%
2017 -8.131.000 7.82%
2018 -7.606.000 -6.9%
2019 -9.810.000 22.47%
2020 -9.081.000 -8.03%
2021 -13.210.000 31.26%
2022 -15.542.000 15%
2023 -4.043.000 -284.42%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

InspireMD, Inc. Capital Expenditure
Year Capital Expenditure Growth
2009 0
2010 0 0%
2011 139.000 100%
2012 290.000 52.07%
2013 202.000 -43.56%
2014 133.000 -51.88%
2015 16.000 -731.25%
2016 49.000 67.35%
2017 258.000 81.01%
2018 67.000 -285.07%
2019 284.000 76.41%
2020 88.000 -222.73%
2021 344.000 74.42%
2022 473.000 27.27%
2023 96.000 -392.71%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

InspireMD, Inc. Equity
Year Equity Growth
2009 1.675
2010 -2.301 172.79%
2011 6.754.000 100.03%
2012 5.386.000 -25.4%
2013 8.639.000 37.65%
2014 -2.787.000 409.97%
2015 -2.946.000 5.4%
2016 4.045.000 172.83%
2017 2.727.000 -48.33%
2018 8.763.000 68.88%
2019 5.383.000 -62.79%
2020 12.163.000 55.74%
2021 33.532.000 63.73%
2022 17.393.000 -92.79%
2023 43.257.000 59.79%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

InspireMD, Inc. Assets
Year Assets Growth
2009 4.925
2010 5.944 17.14%
2011 10.465.000 99.94%
2012 16.014.000 34.65%
2013 20.745.000 22.81%
2014 11.459.000 -81.04%
2015 5.778.000 -98.32%
2016 9.410.000 38.6%
2017 6.107.000 -54.09%
2018 12.288.000 50.3%
2019 9.880.000 -24.37%
2020 17.777.000 44.42%
2021 39.712.000 55.24%
2022 24.653.000 -61.08%
2023 50.020.000 50.71%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

InspireMD, Inc. Liabilities
Year Liabilities Growth
2009 3.250
2010 8.245 60.58%
2011 3.711.000 99.78%
2012 10.628.000 65.08%
2013 15.327.000 30.66%
2014 14.246.000 -7.59%
2015 8.724.000 -63.3%
2016 5.365.000 -62.61%
2017 3.380.000 -58.73%
2018 3.525.000 4.11%
2019 4.497.000 21.61%
2020 5.614.000 19.9%
2021 6.180.000 9.16%
2022 7.260.000 14.88%
2023 6.763.000 -7.35%

InspireMD, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.16
Net Income per Share
-0.57
Price to Earning Ratio
-5.05x
Price To Sales Ratio
11.26x
POCF Ratio
-6.31
PFCF Ratio
-3.93
Price to Book Ratio
2.25
EV to Sales
8.92
EV Over EBITDA
-2.42
EV to Operating CashFlow
-3.17
EV to FreeCashFlow
-3.12
Earnings Yield
-0.2
FreeCashFlow Yield
-0.25
Market Cap
0,06 Bil.
Enterprise Value
0,05 Bil.
Graham Number
4.03
Graham NetNet
1.13

Income Statement Metrics

Net Income per Share
-0.57
Income Quality
0.8
ROE
-0.64
Return On Assets
-0.42
Return On Capital Employed
-0.51
Net Income per EBT
1
EBT Per Ebit
0.94
Ebit per Revenue
-3.41
Effective Tax Rate
0.01

Margins

Sales, General, & Administrative to Revenue
1.86
Research & Developement to Revenue
1.46
Stock Based Compensation to Revenue
0.59
Gross Profit Margin
0.29
Operating Profit Margin
-3.41
Pretax Profit Margin
-3.2
Net Profit Margin
-3.19

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.45
Free CashFlow per Share
-0.46
Capex to Operating CashFlow
0.02
Capex to Revenue
-0.05
Capex to Depreciation
-1.16
Return on Invested Capital
-0.44
Return on Tangible Assets
-0.38
Days Sales Outstanding
93.95
Days Payables Outstanding
55.16
Days of Inventory on Hand
169.72
Receivables Turnover
3.88
Payables Turnover
6.62
Inventory Turnover
2.15
Capex per Share
-0.01

Balance Sheet

Cash per Share
1,27
Book Value per Share
1,27
Tangible Book Value per Share
1.27
Shareholders Equity per Share
1.27
Interest Debt per Share
0.04
Debt to Equity
0.04
Debt to Assets
0.03
Net Debt to EBITDA
0.64
Current Ratio
9.96
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
0.04
Working Capital
0,04 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
1767500
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

InspireMD, Inc. Dividends
Year Dividends Growth

InspireMD, Inc. Profile

About InspireMD, Inc.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

CEO
Mr. Marvin L. Slosman
Employee
65
Address
4 Menorat Hamaor Street
Tel Aviv, 6744832

InspireMD, Inc. Executives & BODs

InspireMD, Inc. Executives & BODs
# Name Age
1 Mr. Pete Ligotti
Executive Vice President & GM of North America
70
2 Mr. Craig Shore
Chief Financial Officer, Chief Administrative Officer, Secretary & Treasurer
70
3 Mr. Amir Kohen
Vice President of Finance & Human Resources
70
4 Mr. Shane Thomas Gleason
Chief Commercial Officer
70
5 Dr. Patrick A. Verta DVM, M.D., MS Stat
Executive Vice President of Clinical & Medical Affairs
70
6 Mr. Marvin L. Slosman
President, Chief Executive Officer & Director
70
7 Mr. Andrea Tommasoli
Chief Operating Officer
70
8 Dr. Sol J. Barer Ph.D.
Special Advisor to the Board
70

InspireMD, Inc. Competitors